David T. Crawford
Pfizer (United States)(US)
Publications by Year
Research Areas
Estrogen and related hormone effects, Bone health and osteoporosis research, Bone Metabolism and Diseases, Inflammatory mediators and NSAID effects, Bone health and treatments
Most-Cited Works
- → Leptin is a potent stimulator of bone growth in ob/ob mice(2000)518 cited
- → THE HISTOCHEMICAL DEMONSTRATION OF LEUCINE AMINOPEPTIDASE(1957)421 cited
- → Targeted Disruption of the Osteoblast/Osteocyte Factor 45 Gene (OF45) Results in Increased Bone Formation and Bone Mass(2003)296 cited
- → Deletion of the P2X7Nucleotide Receptor Reveals Its Regulatory Roles in Bone Formation and Resorption(2003)289 cited
- → Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models(1998)157 cited
- → Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis(2007)154 cited
- → Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene(1998)131 cited
- → Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model(1997)123 cited
- → A Novel, Non-Prostanoid EP2 Receptor-Selective Prostaglandin E2 Agonist Stimulates Local Bone Formation and Enhances Fracture Healing(2003)116 cited
- → Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.(1995)114 cited